Human uPAR Antibody

Catalog # Availability Size / Price Qty
AF807
AF807-SP
Detection of Human uPAR by Western Blot.
3 Images
Product Details
Citations (13)
FAQs
Supplemental Products
Reviews

Human uPAR Antibody Summary

Species Reactivity
Human
Specificity
Detects human uPAR in direct ELISAs and Western blots. In direct ELISAs, less than 1% cross-reactivity with recombinant mouse uPAR is observed.
Source
Polyclonal Goat IgG
Purification
Antigen Affinity-purified
Immunogen
Mouse myeloma cell line NS0-derived recombinant human uPAR
Leu23-Arg303
Accession # Q03405
Formulation
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. See Certificate of Analysis for details.
*Small pack size (-SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
Label
Unconjugated

Applications

Recommended Concentration
Sample
Western Blot
1 µg/mL
See below
Simple Western
20 µg/mL
MDA‑MB‑231 human breast cancer cells
Immunohistochemistry
1-15 µg/mL
See below
Immunoprecipitation
1 µg/106 cells
U937 human histiocytic lymphoma cell line, see our available Western blot detection antibodies
Blockade of Receptor-ligand Interaction
In a functional ELISA, Human uPAR Antibody (Catalog # AF807) blocks the binding of Recombinant Human uPAR (Catalog # 807-UK) to Recombinant Human u-Plasminogen Activator/Urokinase (Catalog # 1310-SE).The ND50 for this effect is typically <5 µg/mL.
 

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Scientific Data

Western Blot Detection of Human uPAR antibody by Western Blot. View Larger

Detection of Human uPAR by Western Blot. Western blot shows lysates of A431 human epithelial carcinoma cell line and Saos-2 human osteosarcoma cell line. PVDF membrane was probed with 1 µg/mL of Goat Anti-Human uPAR Antigen Affinity-purified Polyclonal Antibody (Catalog # AF807) followed by HRP-conjugated Anti-Goat IgG Secondary Antibody (HAF017). Specific bands were detected for uPAR at approximately 30-60 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1.

Immunohistochemistry uPAR antibody in Human Lung Cancer Tissue by Immunohistochemistry (IHC-P). View Larger

uPAR in Human Lung Cancer Tissue. uPAR was detected in immersion fixed paraffin-embedded sections of human lung cancer tissue using Goat Anti-Human uPAR Antigen Affinity-purified Polyclonal Antibody (Catalog # AF807) at 1 µg/mL for 1 hour at room temperature followed by incubation with the Anti-Goat IgG VisUCyte™ HRP Polymer Antibody (VC004). Tissue was stained using DAB (brown) and counterstained with hematoxylin (blue). Specific staining was localized to cell membranes and cytoplasm. View our protocol for IHC Staining with VisUCyte HRP Polymer Detection Reagents.

Simple Western View Larger

Detection of Human uPAR by Simple WesternTM. Simple Western lane view shows lysates of MDA‑MB‑231 human breast cancer cells, loaded at 0.2 mg/mL. A specific band was detected for uPAR at approximately 74 kDa (as indicated) using 20 µg/mL of Goat Anti-Human uPAR Antigen Affinity-purified Polyclonal Antibody (Catalog # AF807). This experiment was conducted under reducing conditions and using the 12-230kDa separation system.

Reconstitution Calculator

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Preparation and Storage

Reconstitution
Reconstitute at 0.2 mg/mL in sterile PBS. For liquid material, refer to CoA for concentration.
Loading...
Shipping
Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.
Stability & Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: uPAR

The urokinase-type Plasminogen Activator (uPA) is one of two activators that converts the extracellular zymogen plasminogen to plasmin, a serine protease that is involved in a variety of normal and pathological processes that require cell migration and/or tissue destruction. uPA is synthesized and released from cells as a single-chain (sc) pro-enzyme with limited enzymatic activity and is converted to an active two-chain (tc) disulfide-linked active enzyme by plasmin and other specific proteinases. Both the scuPA and tcuPA bind with high-affinity to the cell surface via the glycosyl phosphatidylinositol-linked receptor uPAR which serves to localize the uPA proteolytic activity. The enzymatic activity of scuPA has also been shown to be enhanced by binding to uPAR. Independent of their proteolytic activity, the uPA/uPAR interaction also initiates signal transduction responses resulting in activation of protein tyrosine kinases, gene expression, cell adhesion, and chemotaxis. uPAR can interact with integrins to suppress normal integrin adhesive function and promote adhesion to vitronectin through a high affinity vitronectin binding site on uPAR. uPAR cDNA encodes a 335 amino acid (aa) residue precursor protein with a 22 aa residue signal peptide, five potential N-linked glycosylation sites and a C‑terminal GPI-anchor site. An alternate spliced variant of uPAR encoding a secreted soluble form of uPAR also exists. Human and mouse uPAR share approximately 60% aa sequence identity and the receptor-ligand interaction is strictly species-specific.

References
  1. Dear, A.E. and R.L. Medcalf (1998) Eur. J. Biochemistry 252:185.
Long Name
Urokinase-type Plasminogen Activator Receptor
Entrez Gene IDs
5329 (Human); 18793 (Mouse); 102139334 (Cynomolgus Monkey)
Alternate Names
CD87 antigen; CD87; Monocyte activation antigen Mo3; plasminogen activator, urokinase receptor; PLAUR; uPAR; U-PAR; UPARurokinase plasminogen activator surface receptor; u-plasminogen activator receptor form 2; URKRMO3

Product Datasheets

You must select a language.

x

Citations for Human uPAR Antibody

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

13 Citations: Showing 1 - 10
Filter your results:

Filter by:

  1. Targeting uPA-uPAR interaction to improve intestinal epithelial barrier integrity in inflammatory bowel disease
    Authors: Y Cheng, TR Hall, X Xu, I Yung, D Souza, J Zheng, F Schiele, M Hoffmann, ML Mbow, JP Garnett, J Li
    EBioMedicine, 2021-12-18;75(0):103758.
    Species: Human
    Sample Types: Whole Cells
    Applications: Immunocytochemistry
  2. Variability in CKD Biomarker Studies: Soluble Urokinase Plasminogen Activator Receptor (suPAR) and Kidney Disease Progression in the Chronic Kidney Disease in Children (CKiD) Study
    Authors: Alison G. Abraham, Yunwen Xu, Jennifer L. Roem, Jason H. Greenberg, Darcy K. Weidemann, Venkata S. Sabbisetti et al.
    Kidney Medicine
  3. Senolytic CAR T cells reverse senescence-associated pathologies
    Authors: C Amor, J Feucht, J Leibold, YJ Ho, C Zhu, D Alonso-Cur, J Mansilla-S, JA Boyer, X Li, T Giavridis, A Kulick, S Houlihan, E Peerschke, SL Friedman, V Ponomarev, A Piersigill, M Sadelain, SW Lowe
    Nature, 2020-06-17;0(0):.
    Species: Mouse
    Sample Types: Whole Tissue
    Applications: IHC
  4. Antibody-Drug Conjugates Targeting the Urokinase Receptor (uPAR) as a Possible Treatment of Aggressive Breast Cancer
    Authors: Efrat T. Harel, Penelope M. Drake, Robyn M. Barfield, Irene Lui, Shauna Farr-Jones, Laura Van’t Veer et al.
    Antibodies (Basel)
  5. Integrin-uPAR signaling leads to FRA-1 phosphorylation and enhanced breast cancer invasion
    Authors: MG Annis, V Ouellet, JP Rennhack, S L'Esperanc, C Rancourt, AM Mes-Masson, ER Andrechek, PM Siegel
    Breast Cancer Res., 2018-01-30;20(1):9.
    Species: Human
    Sample Types: Protein
    Applications: Immunoprecipitation
  6. uPAR enhances malignant potential of triple-negative breast cancer by directly interacting with uPA and IGF1R
    Authors: Michaela C. Huber, Rebecca Mall, Herbert Braselmann, Annette Feuchtinger, Sara Molatore, Katrin Lindner et al.
    BMC Cancer
  7. CHK1 and RAD51 activation after DNA damage is regulated via urokinase receptor/TLR4 signaling
    Authors: Pavan B Narayanaswamy, Sergey Tkachuk, Hermann Haller, Inna Dumler, Yulia Kiyan
    Cell Death & Disease
  8. Cyr61 and YB-1 are novel interacting partners of uPAR and elevate the malignancy of triple-negative breast cancer
    Authors: Michaela C. Huber, Natalie Falkenberg, Stefanie M. Hauck, Markus Priller, Herbert Braselmann, Annette Feuchtinger et al.
    Oncotarget
  9. Human Sprouty1 Suppresses Urokinase Receptor-Stimulated Cell Migration and Invasion
    Authors: Ahmed H. Mekkawy, David L. Morris
    ISRN Biochemistry
  10. HAX1 Augments Cell Proliferation, Migration, Adhesion, and Invasion Induced by Urokinase-Type Plasminogen Activator Receptor
    Authors: Ahmed H. Mekkawy, David L. Morris, Mohammad H. Pourgholami
    Journal of Oncology
  11. Ang II-stimulated migration of vascular smooth muscle cells is dependent on LR11 in mice.
    Authors: Jiang M, Bujo H, Ohwaki K, Unoki H, Yamazaki H, Kanaki T, Shibasaki M, Azuma K, Harigaya K, Schneider WJ, Saito Y
    J. Clin. Invest., 2008-08-01;118(8):2733-46.
    Species: Mouse
    Sample Types: Cell Lysates, In Vivo
    Applications: Immunoprecipitation, Neutralization, Western Blot
  12. Modification of kidney barrier function by the urokinase receptor.
    Authors: Wei C, Moller CC, Altintas MM, Li J, Schwarz K, Zacchigna S, Xie L, Henger A, Schmid H, Rastaldi MP, Cowan P, Kretzler M, Parrilla R, Bendayan M, Gupta V, Nikolic B, Kalluri R, Carmeliet P, Mundel P, Reiser J
    Nat. Med., 2007-12-16;14(1):55-63.
    Species: Human
    Sample Types: Whole Cells, Whole Tissue
    Applications: ICC, IHC
  13. Pitavastatin attenuates the PDGF-induced LR11/uPA receptor-mediated migration of smooth muscle cells.
    Authors: Jiang M, Bujo H, Zhu Y, Yamazaki H, Hirayama S, Kanaki T, Shibasaki M, Takahashi K, Schneider WJ, Saito Y
    Biochem. Biophys. Res. Commun., 2006-08-10;348(4):1367-77.
    Species: Rabbit
    Sample Types: Cell Lysates
    Applications: Western Blot

FAQs

No product specific FAQs exist for this product, however you may

View all Antibody FAQs
Loading...

Reviews for Human uPAR Antibody

There are currently no reviews for this product. Be the first to review Human uPAR Antibody and earn rewards!

Have you used Human uPAR Antibody?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review